Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

Neurocrine showcases clinical research at NEI, highlighting large neuropsychiatric disease markets.

What the company is saying

Neurocrine Biosciences is emphasizing its scientific leadership and ongoing research in neuropsychiatric disorders by participating in the 2026 Neuroscience Education Institute Fall Congress. The company is hosting an industry-sponsored session titled 'Inspired by Patients, Driven by Science: The Neurocrine Story,' led by Distinguished Scholar Dimitri E. Grigoriadis, Ph.D., and former Chief Medical Officer Christopher F. O'Brien, M.D. Neurocrine is presenting multiple posters on major depressive disorder, schizophrenia, and tardive dyskinesia, including new analyses and real-world patient data from the KINECT-PRO Phase 4 study of INGREZZA. The announcement highlights the breadth of the company’s research, the development of the Tardive Dyskinesia Impact Scale, and the FDA-approved status of INGREZZA and INGREZZA SPRINKLE for tardive dyskinesia and Huntington's chorea. The company frames its narrative around patient impact, scientific rigor, and the scale of unmet need, referencing prevalence and economic burden figures for major depressive disorder (over 21 million in the U.S.), schizophrenia (24 million worldwide, $150 billion annual U.S. cost), and tardive dyskinesia (at least 800,000 U.S. adults). The tone is factual and scientific, with only a brief aspirational statement about pursuing new medicines.

What the data suggests

The disclosed figures underline the significant market opportunity in neuropsychiatric disorders: over 21 million people in the U.S. live with major depressive disorder, approximately 24 million people worldwide are affected by schizophrenia, and tardive dyskinesia impacts at least 800,000 U.S. adults. The annual associated costs for schizophrenia in the U.S. exceed $150 billion, underscoring the economic stakes. INGREZZA and INGREZZA SPRINKLE are FDA-approved for both tardive dyskinesia and Huntington's chorea, with flexible dosing (40 mg, 60 mg, 80 mg) and a sprinkle formulation for patients with swallowing difficulties. The KINECT-PRO Phase 4 study included a four-week screening, 24-week treatment, and two-week safety follow-up, and used the 11-question Tardive Dyskinesia Impact Scale to assess six domains of patient impact. The announcement does not disclose any financial results, revenue, or operational metrics, so there is no evidence of current commercial performance or financial trajectory. All quantitative data relates to disease prevalence, study design, and product characteristics, not company financials.

Analysis

The announcement is a factual disclosure of Neurocrine Biosciences' participation in a scientific conference, including session schedules, poster topics, and details of clinical studies and FDA-approved products. The tone is neutral and informational, with only one forward-looking statement about pursuing new medicines, which is generic and not tied to any specific financial or operational claim. All other claims are realised and supported by concrete data such as event dates, study designs, and product approvals. There is no mention of new capital outlays, acquisitions, or long-term financial projections. The release does not attempt to inflate expectations or overstate progress; it simply outlines upcoming scientific presentations and summarises existing product information. No measurable financial or operational progress is claimed, and no hype language is present.

Risk flags

• ●The absence of any financial or commercial performance data means investors cannot assess current revenue, profitability, or market share, which limits the ability to gauge near-term value creation.
• ●The focus on large disease prevalence and economic burden figures highlights market opportunity but does not demonstrate Neurocrine's actual penetration or competitive position within these markets.
• ●INGREZZA and INGREZZA SPRINKLE carry significant safety warnings, including risks of depression, suicidal thoughts, allergic reactions, somnolence, QT prolongation, Neuroleptic Malignant Syndrome, and Parkinson-like symptoms, which could affect adoption or trigger regulatory scrutiny.

Bottom line

This announcement is a scientific and clinical showcase, not a financial or commercial update. Neurocrine is highlighting its research depth and FDA-approved products in large neuropsychiatric markets, with over 21 million U.S. adults affected by major depressive disorder, 24 million people worldwide with schizophrenia, and at least 800,000 U.S. adults with tardive dyskinesia. The $150 billion annual U.S. cost of schizophrenia signals a substantial addressable market, but the release provides no data on Neurocrine's actual sales, growth, or market share. Investors receive clear evidence of ongoing scientific activity and regulatory approvals but no insight into current or projected financial performance. The most important takeaway is the scale of the diseases targeted and the company’s established presence in the treatment landscape, but actionable investment conclusions require future disclosures of commercial metrics or clinical trial outcomes.

Announcement summary

(NASDAQ:NBIX) Neurocrine Biosciences, Inc. announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, held November 5-8 in Colorado Springs, Colorado. The company will host an industry-sponsored session titled "Inspired by Patients, Driven by Science: The Neurocrine Story" on November 6 from 6:45-7:45 p.m. MT, presented by Dimitri E. Grigoriadis, Ph.D., Distinguished Scholar, and Christopher F. O'Brien, M.D., Former Chief Medical Officer. Neurocrine will present multiple posters on November 7 from 2:40-3:40 p.m. MT, covering major depressive disorder (MDD), schizophrenia, and tardive dyskinesia (TD). MDD presentations include analyses of glutamatergic dysfunction, cognitive impairment, and antidepressant treatment patterns. Schizophrenia research focuses on cardiometabolic comorbidities following oral atypical antipsychotic initiation. TD presentations highlight the impact of TD on employment and productivity, results from the KINECT-PRO™ study evaluating INGREZZA® (valbenazine) on quality of life, and evidence-based recommendations for treating TD with VMAT2 inhibitors. The KINECT-PRO™ Phase 4 study evaluated patient-reported outcomes for INGREZZA in a real-world TD population, with a four-week screening period, 24-week treatment period (initial 40 mg once-daily, then flexible dosing of 40 mg, 60 mg, or 80 mg), and two-week safety follow-up. The Tardive Dyskinesia Impact Scale (TDIS™), developed by Neurocrine, is a validated patient-reported outcome measure assessing six domains of TD impact. INGREZZA and INGREZZA SPRINKLE are FDA-approved for treating adults with TD and chorea associated with Huntington's disease, available in 40 mg, 60 mg, and 80 mg capsules, and can be taken once daily with most mental health regimens. INGREZZA selectively inhibits VMAT2 and is unique in offering a sprinkle formulation for patients with swallowing difficulties. According to the World Health Organization, more than 21 million people in the U.S. live with MDD, and approximately 24 million people worldwide are affected by schizophrenia. Annual associated costs for schizophrenia in the U.S. are estimated to be more than $150 billion. TD is estimated to affect at least 800,000 adults in the U.S. INGREZZA and INGREZZA SPRINKLE can cause serious side effects, including depression, suicidal thoughts, allergic reactions, somnolence, QT prolongation, Neuroleptic Malignant Syndrome, and Parkinson-like symptoms. Patients are advised to consult healthcare providers regarding medical conditions and medications before starting INGREZZA or INGREZZA SPRINKLE.

Disagree with this article?